Clinical Trials
15 trialsNCT06481735 2026-05-08
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT06580301 2026-02-06
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2 Recruiting
NCT07333469 2026-01-13
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06883526 2026-01-05
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT04697940 2025-09-19
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
Phase 1/2 Active not recruiting
NCT05554939 2025-08-06
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07008885 2025-06-25
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07009002 2025-06-25
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06014073 2025-05-25
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06323525 2025-05-25
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06376721 2024-04-19
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 1/2 Recruiting
NCT05320380 2023-09-01
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Phase 1/2 Withdrawn
NCT03343665 2020-01-23
Nivo40
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT00089284 2019-08-14
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Northwestern University
Phase 1/2 Terminated